PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY THERAPY • Segmentation by therapy • Comparison by therapy • Hydroxyurea – Market size and forecast 2017-2022 • L-glutamine therapy– Market size and forecast 2017-2022 • Market opportunity by therapy PART 08: CUSTOMER LANDSCAPE PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Introduction of gene therapy • Strategic alliances • Orphan drug designations for sickle-cell anemia PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb • Emmaus Medical • Medunik USA PART 14: APPENDIX • List of abbreviations PART 15: EXPLORE TECHNAVIO Exhibit 01: Parent market Exhibit 02: Global hematology market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Market size and forecast 2017-2022 ($ mn) Exhibit 09: Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2017 Exhibit 18: Therapy – Market share 2017-2022 (%) Exhibit 19: Comparison by therapy Exhibit 20: Hydroxyurea – Market size and forecast 2017-2022 ($ mn) Exhibit 21: Hydroxyurea – Year-over-year growth 2018-2022 (%) Exhibit 22: L-glutamine therapy – Market size and forecast 2017-2022 ($ mn) Exhibit 23: L-glutamine therapy – Year-over-year growth 2018-2022 (%) Exhibit 24: Market opportunity by therapy Exhibit 25: Customer landscape Exhibit 26: Vendor landscape Exhibit 27: Landscape disruption Exhibit 28: Vendors covered Exhibit 29: Vendor classification Exhibit 30: Market positioning of vendors Exhibit 31: Bristol-Myers Squibb - Overview Exhibit 32: Bristol-Myers Squibb – Business segments Exhibit 33: Bristol-Myers Squibb – Organizational developments Exhibit 34: Bristol-Myers Squibb – Geographic focus Exhibit 35: Bristol-Myers Squibb – Segment focus Exhibit 36: Bristol-Myers Squibb – Key offerings Exhibit 37: Bristol-Myers Squibb – Key customers Exhibit 38: Emmaus Medical - Overview Exhibit 39: Emmaus Medical – Organizational developments Exhibit 40: Emmaus Medical – Geographic focus Exhibit 41: Emmaus Medical – Key offerings Exhibit 42: Emmaus Medical – Key customers Exhibit 43: Medunik USA – Overview Exhibit 44: Medunik USA – Organizational developments Exhibit 45: Medunik USA – Key offerings Exhibit 46: Medunik USA – Key customers

Bristol-Myers Squibb Emmaus Medical and Medunik USA